Breaking News Instant updates and real-time market news.

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/23/18
09/23
04:55
09/23/18
04:55

European Society of Retina Specialists to hold a conference

18th Congress of EURETINA will be held in Vienna, Austria on September 20-23.

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

AERI Aerie Pharmaceuticals
$58.50

0.1 (0.17%)

07/13/18
NEED
07/13/18
NO CHANGE
Target $86
NEED
Buy
Aerie Pharmaceuticals price target raised to $86 from $76 at Needham
Needham analyst Serge Belanger raised his price target on Aerie Pharmaceuticals to $86 and kept his Buy rating after hosting investor meetings with its management. The analyst says the company has provided "anecdotal feedback" of a strong initial launch of Rhopressa, with physicians reporting efficacy levels superior to those observed in the clinical trials along with lower incidences of hyperemia. Belanger notes that the management is "increasingly confident" about meeting its $20M-$30M sales guidance for 2018 and "comfortable" with consensus estimates for revenue in FY19.
07/24/18
MZHO
07/24/18
NO CHANGE
Target $77
MZHO
Buy
Mizuho sees 'very high' probability of approval for Aerie's Roclatan
Mizuho analyst Difei Yang sees a "very high" probability of approval for Aerie Pharmaceuticals' Roclatan and expects a launch in mid-2019. The company yesterday announced the acceptance of its new drug application submission and a FDA action date March 14, 2019. Further, Aerie is well positioned to reach break-even without additional capital raising, Yang tells investors in a research note. She sees minimal risk of further dilution to common shareholders and reiterates a Buy rating on the shares with a $77 price target.
08/09/18
COWN
08/09/18
NO CHANGE
COWN
Aerie Pharmaceuticals price target raised to $105 from $100 at Cowen
09/11/18
STFL
09/11/18
NO CHANGE
Target $87
STFL
Buy
Aerie price target raised to $87 after ophthalmologist survey at Stifel
After surveying 60 ophthalmologists on current practices and perspectives on recent entrants to the glaucoma market, namely Bausch Health's (BHC) Vyzulta and Aerie Pharmaceuticals' (AERI) Rhopressa, Stifel analyst Annabel Samimy said the results reaffirmed his view that Rhopressa has the potential to become the leading adjunct agent. The analyst, who said doctor reception to Vyzulta's clinical profile was also stronger than expected, keeps Buy ratings on Bausch Health and Aerie and raised his price target on the latter to $87 from $80.
AGN Allergan
$191.34

-1.11 (-0.58%)

09/14/18
WELS
09/14/18
NO CHANGE
WELS
Outperform
Wells says 'so far so good' at Allergan aesthetics day
Wells Fargo analyst David Maris says Allergan's focus thus far at its aesthetics day has been on future market growth and new product rollouts. The stock is not moving much on today's news as investors want to understand that the company's plans can be accomplished within the same margin structure and not at the expense of earnings growth, Maris tells investors in an intraday research note. He believes this may be clarified later in the day and points out that some of the pipeline products will not be rolled out for some time. "So we are early in the all-day meeting, but so far, so good," Maris writes, while maintaining his Outperform rating on Allergan.
09/17/18
09/17/18
DOWNGRADE

Market Perform
Revance downgraded to Market Perform after Allergan data at JMP Securities
As previously reported, JMP Securities analyst Donald Ellis downgraded Revance (RVNC) to Market Perform from Outperform after Allergan (AGN) released Botox study data that he said suggests that the longer duration of activity of Revance's RT002 may be partially or primarily due to a "dose" effect. While Ellis doesn't see Allergan conducting the trials needed for an FDA label change, he does think the data will be extensively shared at medical meetings and sees it minimizing the benefit of extended duration claims for RT002 versus Botox.
09/17/18
RHCO
09/17/18
NO CHANGE
Target $218
RHCO
Buy
Allergan price target raised to $218 from $200 at SunTrust
SunTrust analyst John Boris raised his price target on Allergan to $218 and kept his Buy rating, saying the company's Medical Aesthetics Day presentation on Friday supports his view that its markets are "materially under-penetrated". The analyst is positive on the company's portfolio, pipeline, and commercial investment that includes a salesforce expansion of over 20% for Botox/Juvederm and CoolSculpting, which he contends should "allay competitive fears". Boris adds that he is keeping his earnings view for FY18-19, but raises his global sales forecast by FY25 by $880M to $7B.
09/18/18
CANT
09/18/18
NO CHANGE
Target $35
CANT
Overweight
Evolus selloff yesterday not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen sees no fundamental reason for the 12% pullback yesterday in shares of Evolus (EOLS). The stock weakness was partly attributed to the "upbeat and well-attended" investor day held by competitor Allergan (AGN) last Friday, Chen tells investors in a research note. The analyst points out that shares of Revance (RVNC), which also competes with Allergan in the botulinum toxin space, dropped yesterday as well. Chen believes Allergan's investor day renewed concerns that the company is and will remain the leading botulinum toxin/aesthetics player in the space. However, this is nothing new and is already priced into Evolus' valuation, Chen contends. The analyst continues to expect the company's launch of DWP-450 in spring 2019 to exceed "modest expectations." She keeps an Overweight rating on the shares with a $35 price target.
ALIM Alimera Sciences
$1.07

(0.00%)

06/29/18
RILY
06/29/18
INITIATION
Target $2.75
RILY
Buy
Alimera Sciences initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Alimera Sciences with a Buy rating and $2.75 price target.
05/08/18
HCWC
05/08/18
NO CHANGE
Target $2.5
HCWC
Buy
Alimera Sciences price target lowered to $2.50 from $5 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Alimera Sciences to $2.50 to reflect a lower than expected growth rate following the company's Q1 results. The analyst keeps a Buy rating on the shares.
BABY Natus Medical
$34.45

-0.2 (-0.58%)

01/08/18
WBLR
01/08/18
DOWNGRADE
WBLR
Market Perform
Natus Medical downgraded to Market Perform from Outperform at William Blair
02/27/18
ROTH
02/27/18
INITIATION
Target $39
ROTH
Buy
Natus Medical resumed with a Buy at Roth Capital
Roth Capital analyst Scott Henry resumed coverage of Natus Medical with a Buy rating and $39 price target as he believes the recent selloff of the shares following its Q4 earnings miss presents a buying opportunity for investors.
07/12/18
ROTH
07/12/18
NO CHANGE
ROTH
Roth maintains Buy rating on Natus, says CEO change 'not a surprise'
Natus Medical announced Wednesday after the close that CEO Jim Hawkins is retiring and will be immediately replaced by CFO Jonathan Kennedy, and that Natus Q2 revenue guidance range was tightened to $130M-$131M from $129M-131M. Roth Capital analyst Scott Henry said the announcement was "not a surprise," added that the internal choice signals the "business is stable," and concluded that he was encouraged that the transition was not used to lower guidance. Henry maintained a Buy rating and $39 price target on Natus Medical shares, calling it a "good value and turnaround story."
BHC Bausch Health
$24.92

-0.07 (-0.28%)

09/17/18
09/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Reliance Steel (RS) initiated with a Neutral at Citi. 2. Bausch Health (BHC) assumed with an Overweight at Barclays. 3. Stanley Black & Decker (SWK) initiated with an Outperform at Credit Suisse. 4. Aramark (ARMK) initiated with an Outperform at Bernstein. 5. Kraft Heinz (KHC) was assumed with an Underweight at Morgan Stanley, while Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) were assumed with an Equal Weight. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/18
LEHM
09/17/18
INITIATION
Target $29
LEHM
Overweight
Bausch Health assumed with an Overweight at Barclays
Barclays analyst Geoff Meacham assumed coverage of Bausch Health Companies with an Overweight rating and $29 price target.
09/13/18
JEFF
09/13/18
NO CHANGE
Target $27
JEFF
Buy
Bausch bankruptcy risk arguably off table with settlement, says Jefferies
Bausch Health (BHC) yesterday announced an important settlement for Xifaxan with first to file Teva (TEVA), allowing for generic entry in January of 2028, Jefferies analyst David Steinberg tells investors in a research note. One could argue the settlement takes Bausch's bankruptcy risk off the table given the "long runway and greater certainty to future cash flows" from what is the company's most important drug, the analyst contends. Further, the deal could also allow the company to refinance its debt at more attractive terms. Steinberg keeps a Buy rating on Bausch Health with a $27 price target.
09/13/18
HCWC
09/13/18
NO CHANGE
Target $25
HCWC
Neutral
Bausch Health price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Bausch Health (BHC) to $25 after the company reached an agreement to resolve the outstanding intellectual property litigation regarding Xifaxan with Teva's (TEVA) Actavis Laboratories. While the analyst is "enthused" by the agreement, particularly since Actavis was the only entity to have received tentative approval of a generic rifaximin product, he notes that the competitive risks to Xifaxan "are not all in the rear view mirror quite yet." Other factors still remain to be clarified, including the status of the new drug application for Cosmo Pharmaceuticals' Rifamycin, which has an approval decision date of November 16, the analyst adds. Selvaraju keeps a Neutral rating on Bausch Health.
BAYRY Bayer
$0.00

(0.00%)

09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.
09/18/18
09/18/18
UPGRADE

Bayer upgraded to Buy from Hold at M.M. Warburg
M.M. Warburg analyst Ulrich Huwald upgraded Bayer to Buy and raised his price target for the shares to EUR 88.50 from EUR 85.
09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
ELXMF Ellex Medical Lasers
$0.00

(0.00%)

12/06/17
MAXM
12/06/17
INITIATION
Target $1.5
MAXM
Buy
Ellex Medical Lasers initiated with a Buy at Maxim
Maxim analyst Anthony Vendetti initiated Ellex Medical Lasers Buy rating and a price target of $1.50. Vendetti says his channel checks suggest that the company has "the best-in-class product for minimally invasive glaucoma surgery - MIGS - which is the fastest-growing segment of the glaucoma treatment market". The analyst also points to the anticipated June 2018 clinical trial results for the company's retinal rejuvenation therapy, which he calls "a huge growth opportunity as potentially the only treatment that significantly slows the progression of early age-related macular degeneration".
GKOS Glaukos
$58.78

-1.69 (-2.79%)

09/10/18
SPHN
09/10/18
NO CHANGE
Target $70
SPHN
Overweight
Glaukos price target raised to $70 from $57 at Stephens
Stephens analyst Chris Cooley raised his price target on Glaukos (GKOS) shares to $70 from $57 following talks with key opinion leaders and a review of the FDA MAUDE database. The KOL discussions and database review lead Cooley to conclude that the adverse event profile that lead Novartis (NVS) to withdraw the CyPass Micro-Stent is device specific and not indicative of a class issue and that Glaukos' long-term growth prospects and strategic value are both notably enhanced by the event. He maintains an Overweight rating on Glaukos shares.
09/05/18
BMOC
09/05/18
NO CHANGE
Target $68
BMOC
Market Perform
Glaukos price target raised to $68 from $59 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Glaukos to $68 and also raised her FY18 revenue forecast to $177.1M from $165.5M while maintaining her Market Perform rating. The analyst cites her proprietary survey of benefits for the Glaukos product iStent coming from the cessation of Alcon's CyPass, with 24% of responding physicians noting that it represents a "class effect", 29% still undecided, and the remaining 48% suggesting that CyPass cessation is specific to the product. The analyst expects the market "dislocation" to continue until the FDA approval of Ivantis' Hydrus and Glaukos's launch of iStent Inject are absorbed, with limited upside in Glaukos stock anticipated for the next 4-6 months.
08/31/18
PIPR
08/31/18
NO CHANGE
Target $73
PIPR
Overweight
Glaukos price target raised to $73 from $55 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Glaukos (GKOS) to $73 and keeps an Overweight rating on the shares. After digging into the issue, the analyst believes the issue facing Novartis' (NVS) Alcon is specific to CyPass and not a minimally invasive glaucoma surgery "category killer." Given the design of Glaukos' iStent and where it is placed, the stent migration issue does not occur, so it does not encounter this issue at a level that can cause vision loss, O'Brien tells investors in a research note. Further, the analyst does not believe there is an easy fix for Alcon's CyPass. And even if the product does come back on the market, it will likely "face a major hurdle to overcome amongst clinicians," O'Brien contends. As such, he expects Glaukos to recapture the majority of its lost market share. The analyst keeps an Overweight rating on the shares.
08/30/18
WELS
08/30/18
NO CHANGE
Target $74
WELS
Outperform
Glaukos price target raised to $74 from $50 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Glaukos (GKOS) to $74 from $50, while reiterating an Outperform rating on the shares. The analyst notes that Novartis (NVS) stated it was removing its CyPass micro invasive glaucoma surgery device from the global market due to 5-year data, which showed statistically significant endothelial cell loss for CyPass compared to the group, who underwent cataract surgery alone. The analyst believes the issue is CyPass-specific and expects Glaukos to materially benefit from Alcon's exit beginning in Q4 and years ahead.
IRIX IRIDEX
$6.52

0.08 (1.24%)

11/03/17
ROTH
11/03/17
INITIATION
Target $13
ROTH
Buy
IRIDEX resumed with a Buy at Roth Capital
Roth Capital analyst Scott Henry resumed coverage of IRIDEX with a Buy rating and $13 price target.
11/03/17
11/03/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. YogaWorks (YOGA) initiated with an Outperform at Imperial Capital. 2. IRIDEX (IRIX) resumed with a Buy at Roth Capital. 3. TE Connectivity (TEL) initiated with an Outperform at Baird. 4. Pilgrim's Pride (PPC), Sanderson Farms (SAFM), and Tyson Foods (TSN) were initiated with an Equal Weight at Morgan Stanley, while Hormel Foods (HRL) initiated with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/31/18
ROTH
08/31/18
NO CHANGE
ROTH
Buy
IRIDEX showing material progress in KOL-driven strategy, says Roth Capital
After IRIDEX announced that U.S. News and World Report said that 35 of the top 39 "Best Hospitals for Ophthalmology" currently use the Cyclo G6 Glaucoma Laser System, Roth Capital analyst Scott Henry said he was encouraged to learn that the extent to which leading centers had been using the system is broader than he previously assumed. The analyst, who sees this as evidence of the material progress IRIDEX is making in executing its Key Opinion Leader, or KOL, driven commercial strategy, maintains a Buy rating on the shares.
JNJ Johnson & Johnson
$142.85

0.85 (0.60%)

08/27/18
WBLR
08/27/18
NO CHANGE
WBLR
Outperform
Mariner failure removes potential Portola competition, says William Blair
William Blair analyst Matt Phipps says that while the failure of Johnson & Johnson's (JNJ) Mariner trial removes potential competition Portola Pharmaceuticals' (PTLA) Bevyxxa, which is positive, "significant work" is still needed to gain adoption of Bevyxxa in the United States. As such, the Mariner results do not significantly alter the near-term headwinds for Bevyxxa, Phipps tells investors in a research note. The analyst believes getting beyond the Mariner presentation allows investors to focus on the opportunity for Andexxa, which he still thinks is "significant." He points out that Portola remains on track to file the prior approval supplement for the second-generation manufacturing process of Andexxa in the coming days, which would provide sufficient supply for 1,000 hospitals in the United States and expansion into Europe. Phipps keeps an Outperform rating on Portola Pharmaceuticals, which is up 5% to $29.60 in premarket trading.
08/27/18
MSCO
08/27/18
NO CHANGE
MSCO
Equal Weight
Portola may be up 'somewhat' on Xarelto trial failure, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted the failure of Johnson & Johnson's (JNJ)MARINER study, which was examining Xarelto, a competing anticogulant to Portola's (PTLA) BevyxXa. MARINER's failure to demonstrate a statistically significant result of reducing symptomatic VTE or death due to VTE is expected by Harrison to send Portola shares up "somewhat," but he believes most investors had already lowered their expectations for the BevyxXa franchise after the Q2 report, making the impact modest. He maintains an Equal Weight rating on Portola shares, which are up 3% to $29 per share in early trading.
09/14/18
WELS
09/14/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $150 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Johnson & Johnson to $160 after the company hosted an investor call to provide an update on its Pharmaceuticals business. The analyst heard no strategic change to the business saying J&J maintains focus on its six key therapeutic areas and remains agnostic to the source of innovation. While the company did not provide 2019 guidance, management's tone came across as confident in the business outlook, Biegelsen tells investors in a research note. He keeps an Outperform rating on Johnson & Johnson.
NITE Nightstar Therapeutics
$25.64

-1.71 (-6.25%)

06/27/18
OPCO
06/27/18
DOWNGRADE
OPCO
Perform
Nightstar Therapeutics downgraded to Perform from Outperform at Oppenheimer
08/22/18
JANY
08/22/18
INITIATION
JANY
Buy
Nightstar Therapeutics initiated with a Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong initiated Nightstar Therapeutics with a Buy.
08/22/18
08/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BJ's Restaurants (BJRI) initiated with a Buy at Maxim. 2. Nightstar Therapeutics (NITE) initiated with a Buy at Janney Montgomery Scott. 3. Endava (DAVA) initiated with a Hold at Deutsche Bank. 4. Cardiovascular Systems (CSII) initiated with a Buy at Stifel. 5. Wright Medical (WMGI) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/04/18
MZHO
09/04/18
NO CHANGE
Target $24
MZHO
Buy
Nightstar Therapeutics price target raised to $24 from $20 at Mizuho
Mizuho analyst Difei Yang raised her price target for Nightstar Therapeutics to $24 saying she'd be a buyer of the stock ahead of the preliminary data from the company's X-linked retinitis pigmentosa program on September 22 at the European Society of Retina Specialists 2018 Meeting in Vienna, Austria. The data will be an "important catalyst" as positive results would further validate the Nightstar platform and be a "significant de-risking event," Yang tells investors in a research note. She keeps a Buy rating on Nightstar Therapeutics.
NVS Novartis
$85.46

-0.505 (-0.59%)

09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/11/18
09/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at Canaccord with analyst Camilo Lyon saying he believes Nike has regained its footing and is marching back to form following two years of a soft product cycle, margin compression, and market share declines. 2. Novartis (NVS) upgraded to Buy from Neutral at Citi and to Neutral from Underperform at Exane BNP Paribas. 3. Darden (DRI) upgraded to Buy from Neutral at Goldman Sachs while Bloomin' Brands (BLMN) was upgraded to Neutral from Sell. 4. South Jersey Industries (SJI) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying the company's "superior" growth potential is coming into focus while its shares trade at a discount to peers. 5. Snap (SNAP) upgraded to Outperform from Neutral at Wedbush with analyst Michael Pachter noting that decelerating growth trends, fierce competition for user mindshare and advertiser dollars, and a history of being hugely unprofitable have kept him on the sidelines, but recent management changes and improved execution have led him to update his outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/18
SBSH
09/11/18
UPGRADE
SBSH
Buy
Novartis upgraded to Buy from Neutral at Citi
Citi upgraded Novartis to Buy from Neutral. Exane BNP Paribas also upgraded the shares this morning to Neutral.
OCUL Ocular Therapeutix
$6.45

0.03 (0.47%)

01/19/18
BTIG
01/19/18
UPGRADE
BTIG
Buy
Ocular Therapeutix upgraded to Buy from Neutral at BTIG
01/19/18
BTIG
01/19/18
UPGRADE
Target $9
BTIG
Buy
Ocular Therapeutix upgraded to Buy from Neutral at BTIG
As reported earlier, BTIG analyst Dane Leone upgraded Ocular Therapeutix to Buy from Neutral with a price target of $9. Leone cites the new management's reset of expectation for a resubmission of the Dextenza NDA for post-surgical cataract patients for the first half of this year, which sets a "reasonable 6-month review table" to have approval by year-end. The analyst models Dextenza generating about $16M in sales in 2019 and rising to $116M by 2022.
03/08/18
CANT
03/08/18
NO CHANGE
Target $22
CANT
Overweight
Cantor Fitzgerald says Ocular Therapeutix set up for 'momentous' 2018
Following Ocular Therapeutix's Q4 report and call, during which the company reiterated its guidance to resubmit its application for DEXTENZA in the first half of 2018 and said it continues to anticipate the readout of its Phase 3 OTX-TP study in glaucoma in the fourth quarter, Cantor Fitzgerald analyst Elemer Piros said he expects a "momentous" year for the company. He keeps an Overweight rating on Ocular and raised his price target on the stock to $22 from $21.
09/06/18
PIPR
09/06/18
INITIATION
Target $14
PIPR
Overweight
Ocular Therapeutix initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro initiated Ocular Therapeutix with an Overweight rating and $14 price target, stating that he is confident that the issues raised in Dextenza's CRLs have been addressed well enough to warrant an FDA approval before the end of 2018. He believes Dextenza U.S. sales in the post-surgical setting can rise to $250M by 2025.
RHHBY Roche
$0.00

(0.00%)

09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.
09/17/18
OPCO
09/17/18
NO CHANGE
Target $400
OPCO
Outperform
Roche's AD updates provide favorable read-through for Biogen, says Oppenheimer
Oppenheimer analyst Jay Olson says he remain bullish on Biogen (BIIB), telling investors in a research note that he believes Roche's (RHHBY) Alzheimer's disease updates provide a favorable read-through for Biogen's own Alzheimer's disease portfolio. Among the takeaways from Roche's pipeline update are the importance of a reduction in amyloid, confidence in dose escalation, epidemiology estimate and reimbursement commentary. Olson, who has an Outperform rating and $400 price target on Biogen, says he believes shares are undervalued based on his view that the company's leadership position in neuroscience should deliver long-term growth.
09/13/18
CANT
09/13/18
NO CHANGE
Target $36
CANT
Overweight
Cantor boosts Corbus target to Street-high $36 after Roche study 'fell short'
Cantor Fitzgerald analyst Elemer Piros raised his price target for Corbus Pharmaceuticals to a Street-high $36 following abstracts from the American College of Rheumatology meeting, which is taking place in October. Among the abstracts, Phase 3 data from Roche's (RHHBY) Phase 3 systemic sclerosis study with competitive agent tocilizumab fell short on its primary endpoint in modified Rodnan skin score, Piros tells investors in a research note partially titled "Lenabasum's Gain, Following Tocilizumab's Loss." The analyst believes the results establish Corbus' lenabasum, in Phase 3 now for systemic sclerosis, as the" only compelling treatment option for patients in this rare and life-threatening disease." Further, Additionally, Piros believes lenabasum's resolution of inflammatory activity was further validated in an assessment of interferon response in patients with dermatomyositis. The analyst reiterates an Overweight rating on the shares. Corbus Pharmaceuticals in afternoon trading is up 7.5c to $5.28.
09/10/18
09/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Inogen (INGN) downgraded to Buy from Strong Buy at Needham with analyst Mike Matson citing the potential for slower growth as tougher comps start in the second half of 2018, along with a tighter level of competition from Resmed (RMD) and valuation following the 122% year-to-date run-up in the stock price. 2. UnitedHealth (UNH) and Anthem (ANTM) were downgraded to Neutral from Buy at Citi. 3. Constellation Brands (STZ) downgraded to Hold from Buy at SunTrust with analyst William Chappell saying the company's recent $4B investment in Canopy Growth may "keep a cloud" over the stock for the next few quarters, as there is "little certainty" in the deal's revenue or profit potential. 4. Darden (DRI) downgraded to Neutral from Outperform at Baird with analyst David Tarantino citing its recent strength and recommends a more disciplined approach to buying in the short-term as many restaurant names begin to look extended. 5. Roche (RHHBY) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SHPG Shire
$178.32

-1.68 (-0.93%)

05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
09/04/18
BERN
09/04/18
DOWNGRADE
BERN
Market Perform
Shire downgraded to Market Perform from Outperform at Bernstein
09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
STAA STAAR Surgical
$47.00

-0.9 (-1.88%)

09/14/18
ADAM
09/14/18
NO CHANGE
Target $55
ADAM
Buy
STAAR Surgical price target raised to $55 from $43 at Canaccord
Canaccord analyst Jason Mills raised his price target to $55 from $43 following the FDA approval of its Toric ICL. The analyst said it represent tangible progress for the company along the path of tapping into the U.S. refractive market and could also serve as upside to current guidance. Mills reiterated his Buy rating on STAAR Surgical shares.
08/06/18
BNCH
08/06/18
INITIATION
Target $45
BNCH
Buy
STAAR Surgical transitioned with a Buy at Benchmark
Benchmark transitioned coverage of STAAR Surgical to analyst Bruce Jackson, who sees the company having achieved a major milestone this quarter with full resolution of the FDA Warning Letter, clearing the way for the possible approval and launch of the Toric ICL later this year. Jackson has a Buy rating and $45 price target on STAAR Surgical shares.
08/02/18
ADAM
08/02/18
NO CHANGE
Target $43
ADAM
Buy
STAAR Surgical price target raised to $43 from $32 at Canaccord
Canaccord analyst Jason Mills raised his price target on STAAR Surgical to $43 from $32 following its Q2 results. The analyst said its key franchise ICL accelerated further in Q2, demonstrating the paradigm in refractive vision correction is changing in STAAR's favor. He noted the guidance was raised and he sees momentum continuing. Mills reiterated his Buy rating on STAAR Surgical shares.
06/20/18
ADAM
06/20/18
NO CHANGE
Target $32
ADAM
Buy
STAAR Surgical price target raised to $32 from $23 at Canaccord
Canaccord analyst Jason Mills raised his price target for STAAR Surgical to $32 from $23 as he believes that with the FDA warning letter resolved, he sees it as primed to take off in the U.S. The analyst views the Warning Letter lift as a bullish catalyst for the stock and the company, with the enormous potential growth engine that is the U.S. market now fully accessible to STAAR. With presbyopia and with full entry into the U.S. market acting as major growth drivers, the analyst expects sustained, double-digit organic growth into the next decade and beyond. He reiterates a Buy rating on the shares.
TMDI Titan Medical
$2.24

0.02 (0.90%)

09/17/18
NORL
09/17/18
INITIATION
Target $6
NORL
Outperform
Titan Medical initiated with an Outperform at Northland
Northland analyst Suraj Kalia initiated Titan Medical with an Outperform and $6 price target.saying its an emerging player in the single-port robotic surgery space, and the only other company besides Intuitive Surgical to offer a platform for targeted segments, and an attractive micro-cap play.
TTNP Titan Pharmaceuticals
$0.22

-0.2833 (-56.66%)

11/10/17
ROTH
11/10/17
DOWNGRADE
ROTH
Neutral
Titan Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
11/10/17
ROTH
11/10/17
DOWNGRADE
Target $2
ROTH
Neutral
Titan downgraded to Neutral with $2 target at Roth Capital
Roth Capital analyst Scott Henry downgraded Titan Pharmaceuticals to Neutral from Buy and cut his price target for the shares to $2 from $6. Probuphine continues to miss estimates and visibility into a positive inflection point remains lacking, Henry tells investors in a research note following Titan's Q3 results.

TODAY'S FREE FLY STORIES

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27
Hot Stocks
BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study »

BioLineRx (BLRX)…

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

ADAP

Adaptimmune

$10.79

-0.09 (-0.83%)

13:22
10/21/18
10/21
13:22
10/21/18
13:22
Hot Stocks
Adaptimmune presents updated data from ongoing MAGE-A10, MAGE-A4 studies »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26
Hot Stocks
Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

12:18
10/21/18
10/21
12:18
10/21/18
12:18
Hot Stocks
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer »

Tesaro summarized updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

AVB

AvalonBay

$178.01

1.725 (0.98%)

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
AvalonBay rating change  »

AvalonBay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
Morgan Stanley China hardware analyst to hold analyst/industry conference call »

China Hardware Tech…

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.